source
- Former Spark co-founder Steven Altschuler launches new immune-resetting biotechSteven Altschuler, who co-founded Spark Therapeutics, has announced the formation of a new biotech that aims to reset the immune system. The venture is positioned to address autoimmune diseases, a…
- Novo Nordisk licenses weekly oral obesity peptide from Hengrui in up to $2.6 billion dealNovo Nordisk has signed a licensing agreement with China's Hengrui Pharma for a once‑weekly oral peptide, HRS‑1596, aimed at obesity and other metabolic conditions. Novo will pay $300 million upfr…